Clinical Trials | November 14, 2025
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Fenebrutinib targets cells in the immune system known as B cells and microglia
Fenebrutinib targets cells in the immune system known as B cells and microglia
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
This partnership has led to a 10% boost in delivery speed
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Subscribe To Our Newsletter & Stay Updated
